Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 4—April 2012


Dengue in Patients with Central Nervous System Manifestations, Brazil

Fernanda AraújoComments to Author , Rita Nogueira, Maurício de Sousa Araújo, Anne Perdigão, Luciano Cavalcanti, Raimunda Brilhante, Marcos Rocha, Dina Feitosa Vilar, Suzana Silveira Holanda, Deborah de Melo Braga, and José Sidrim
Author affiliations: State Health Secretariat of Ceará, Fortaleza, Ceará, Brazil (F.M.C. Araújo, A.C.B. Perdigão, D.C.L. Feitosa Vilar, S.G. Silveira Holanda and D.N. de Melo Braga); Oswaldo Cruz Institute, Rio de Janeiro, Rio de Janeiro, Brazil (R.M.R. Nogueira); Dr. José Frota Institute, Fortaleza (M. de Sousa Araújo); Federal University of Ceará, Fortaleza (L.P.G., Cavalcanti, F.M. de Carvalho Araújo, J.J. da Costa Sidrim, R.S.N. Brilhante, M.F.G. Rocha); State University of Ceará, Fortaleza (A.C.B. Perdigão); College Christus, Fortaleza (L.P.G. Cavalcanti)

Main Article

Table 2

Risk for death among patients with meningitis/meningoencephalitis with DENV+ versus DENV– cerebrospinal fluid test results, Brazil, 2005–2008†

Outcome DENV+ DENV– Total
Death 4 (14.8) 23 (85.2) 27 (100)
Recovery 4 (2.2) 178 (97.8) 182 (100)

*Values are no. (%) patients. Relative risk 6.74 (95% CI 1.79–25.38); p<0.0109. DENV, dengue virus; –, negative; +, positive.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO